Parkinson’s Trial in Loir-et-Cher: Antidiabetics
- An event held Tuesday, April 22, at La Chaussée-Saint-Victor, France, aimed to dispel common misconceptions about Parkinson's disease.
- Approximately 80 people attended the event,which coincided with World Parkinson's Day on April 11.
- Marie Fuzzati, scientific director of France Parkinson, stated that while treatments can improve symptoms, "currently you can improve symptoms with diffrent treatments, but there is nothing to slow...
Understanding Parkinson’s Disease: Beyond the Tremors
Table of Contents
- Understanding Parkinson’s Disease: Beyond the Tremors
- Understanding Parkinson’s Disease: Your Questions answered
- What is Parkinson’s Disease?
- who Does Parkinson’s Disease Affect?
- What are the Current Treatments for Parkinson’s Disease?
- How Does Parkinson’s Disease affect the Brain?
- Why Can’t Dopamine Be Directly Administered?
- What is Drug Repurposing?
- Is Repurposing Drugs a Promising Approach?
- What is the Role of Physical Activity in Managing Parkinson’s?
- Where Can I Find More Information About Parkinson’s Disease?
- Key Research and Treatment areas: A Summary
An event held Tuesday, April 22, at La Chaussée-Saint-Victor, France, aimed to dispel common misconceptions about Parkinson’s disease. Organized by the Departmental Committee of france Parkinson, the event highlighted the complexities of the neurological disorder, which affects an estimated 270,000 people in France. The discussion emphasized that Parkinson’s is not solely a disease of the elderly,as illustrated by speaker Guillaume Brachet,who was diagnosed at age 29.
Approximately 80 people attended the event,which coincided with World Parkinson’s Day on April 11. France Parkinson 41 hosted the free event to provide updated information on the disease and current treatment options. Olivia larorye, diagnosed with early-onset Parkinson’s at 47 and undergoing neurostimulation with brain implants, introduced herself as the new departmental delegate, succeeding Elisabeth David.
Current Treatments and Research Directions
Marie Fuzzati, scientific director of France Parkinson, stated that while treatments can improve symptoms, “currently you can improve symptoms with diffrent treatments, but there is nothing to slow down the progression of the disease. If not to use physical activity.” She added that current research is focused on both symptom management and slowing disease progression.brachet, a pharmacist and researcher from Fondettes, Indre-et-Loire, discussed his work with Cxs Therapeutics. Hélène Sagne, a speech therapist from Blois, emphasized the importance of speech therapy in maintaining patients’ vocal and articulatory abilities but noted a shortage of available services and long waiting lists.
The Parkinsonian Brain: A Simplified explanation
Fuzzati, a researcher for 15 years, explained the biological basis of Parkinson’s: “In a simplified way, we lose the black substance that can be observed in the brain.” She elaborated that the dopaminergic neurons within this substance control automatic movements, requiring notable energy. Their degeneration disrupts brain mechanisms. Fuzzati noted that dopamine itself cannot be directly administered because of the blood-brain barrier. Instead, levodopa, a precursor to dopamine, is prescribed with inhibitors to facilitate its passage into the brain.
Repurposing Drugs: A Key Research Strategy
Researchers are actively exploring the repurposing of existing drugs to treat Parkinson’s symptoms. This involves using drugs already approved for other conditions, such as antidiabetics, due to observed links between diabetes and Parkinson’s disease. this approach can considerably accelerate clinical research. Brachet’s research focuses on this strategy, with hopes for drug authorization by 2030. He cautioned that while the prospect is exciting, clinical trials may not always be conclusive. He declined to name the specific drug, stating, “If I gave you the name of this drug it would be useless because we do not yet have proof that it works for Parkinson patients, nor good concentrations.” Marketing authorization is still pending.
The Importance of Physical Activity
Physical activity remains a primary recommendation for managing Parkinson’s disease.Experts advise 30 minutes of intense daily activity to stimulate natural dopamine production. France Parkinson offers adapted activities in Blois, Romorantin, and Vendôme.
For more information, contact Comite41@franceparkinson.fr or call 06.58.30.15.14.
Understanding Parkinson’s Disease: Your Questions answered
This article answers common questions about Parkinson’s disease, based on information shared at a recent event organized by France Parkinson.
What is Parkinson’s Disease?
Parkinson’s disease is a progressive neurological disorder affecting the brain. It impacts movement and can cause a range of symptoms.
who Does Parkinson’s Disease Affect?
Parkinson’s affects an estimated 270,000 people in France. While frequently enough associated with older adults, it can also affect younger individuals. At the event, speaker Guillaume Brachet shared that he was diagnosed at age 29. Olivia larorye, diagnosed with early-onset Parkinson’s at 47, also spoke at the event.
What are the Current Treatments for Parkinson’s Disease?
Currently, treatments can improve the symptoms of Parkinson’s disease, but there is nothing to slow down the disease’s progression (besides physical activity). Research is ongoing to both manage symptoms and find ways to slow the disease’s progress.
How Does Parkinson’s Disease affect the Brain?
Marie Fuzzati, scientific director of France Parkinson, explained that Parkinson’s involves the loss of the “black substance” in the brain. This substance contains dopaminergic neurons that control movements.Their degeneration disrupts brain function.
Why Can’t Dopamine Be Directly Administered?
Dopamine itself cannot be directly administered because of the blood-brain barrier. Rather, levodopa, a precursor to dopamine, is prescribed with inhibitors to help it cross into the brain.
What is Drug Repurposing?
Drug repurposing involves using existing drugs, approved for other conditions, to treat parkinson’s symptoms. Researchers are exploring drugs like antidiabetics due to links between diabetes and Parkinson’s disease. This approach can speed up research.
Is Repurposing Drugs a Promising Approach?
Guillaume Brachet’s research focuses on drug repurposing, with hopes for drug authorization by 2030.however, he cautioned that clinical trials may not always be conclusive. He could not name the drug, as proof of its effectiveness for Parkinson patients is still pending before marketing authorization.
What is the Role of Physical Activity in Managing Parkinson’s?
Physical activity is a primary suggestion for managing Parkinson’s disease. Experts advise 30 minutes of intense daily activity to stimulate natural dopamine production. France Parkinson offers adapted activities in Blois, Romorantin, and Vendôme.
Where Can I Find More Information About Parkinson’s Disease?
For more information, contact Comite41@franceparkinson.fr or call 06.58.30.15.14.
Key Research and Treatment areas: A Summary
Here’s a fast overview of the key takeaways:
| Area | Details |
|---|---|
| Current Treatments | Focus on symptom management; physical activity is key. |
| research Directions | Symptom management and slowing disease progression. |
| Drug Repurposing | Exploring existing drugs (e.g.,antidiabetics) to treat symptoms; potentially faster clinical research. |
| Physical Activity | Recommended: 30 minutes of intense daily activity to stimulate dopamine. |